SAVA
Cassava Sciences, Inc.
30.32
-
0.98
3.13%
2 x 30.24
2 x 30.41
bid
ask
2 @ 04:00 PM
30.78+0.46 (1.51%)
Bearish
90
Bullish
160
sentiment
29.63
day range
32.30
8.79
52 week range
42.20
Prev Close31.30
Open31.79
Low29.63
High32.30
Volume1.97M
Avg. Volume3.47M
Market Cap1.45B
Inst. Own28.37%
Beta-0.62
Short Ratio4.18
Div & Yield0.00 /
EPS-2.83
P/E0.00
1yr Target103.00
50day MA23.04
200day MA22.31
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA) | news.google.com • |
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8% | news.google.com • |
(SAVA) Technical Pivots with Risk Controls | news.google.com • |
Is Sava, druzba za upravljanje in financiranje, d.d.'s (LJSE:SAVR) Stock Price Struggling As A Result Of Its Mixed Financials? | news.google.com • |
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference | globenewswire.com • |
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid? | marketbeat.com • |
Profile
...
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-05 | 2024-09 | -1.37 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | -0.44 | -1.28 | -0.84 | -190.91% |
2024-05-10 | 2024-03 | -0.51 | -1.41 | -0.9 | -176.47% |
2024-02-28 | 2023-12 | -0.4 | -0.5 | -0.1 | -25.00% |
2023-11-07 | 2023-09 | -0.9 | -0.61 | 0.29 | 32.22% |
2023-08-03 | 2023-06 | -0.58 | -0.63 | -0.05 | -8.62% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-08 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-05 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-23 | HC Wainwright & Co. | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-10-02 | ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-05-23 | BARBIER REMI | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
2024-04-22 | BARRY RICHARD J | Director | 0.00 | Conversion of Exercise of derivative security |
2022-10-02 | FRIEDMANN NADAV | Officer and Director | 80.05K | Conversion of Exercise of derivative security |
2023-04-30 | GUSSIN ROBERT Z | Director | 10.62K | Conversion of Exercise of derivative security |
2024-04-17 | KUPIEC JAMES WILLIAM | Officer | 4.00K | Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 2.75M | 67.35M | 6.54% |
2023-06-29 | Vanguard Group Inc | 2.25M | 55.16M | 5.36% |
2023-06-29 | State Street Corporation | 952.09K | 23.35M | 2.27% |
2023-06-29 | Geode Capital Management, LLC | 803.31K | 19.70M | 1.91% |
2023-06-29 | Gallacher Capital Management LLC | 583.29K | 14.30M | 1.39% |
2023-06-29 | Northern Trust Corporation | 370.64K | 9.09M | 0.88% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.23M | 30.21M | 2.94% |
2023-08-30 | iShares Russell 2000 ETF | 908.42K | 19.05M | 2.16% |
2023-06-29 | Vanguard Extended Market Index Fund | 542.35K | 13.30M | 1.29% |
2023-07-30 | Fidelity Small Cap Index Fund | 353.09K | 7.76M | 0.84% |
2023-08-30 | iShares Russell 2000 Growth ETF | 333.17K | 6.99M | 0.79% |
2023-05-30 | Fidelity Extended Market Index Fund | 202.34K | 4.60M | 0.48% |
Dividend
...
Dividend | Date |
---|---|
0.75 | 2012-12-13 |
2 | 2010-12-13 |
Split
...
Split | Date |
---|---|
1 : 7 | 2017-05-10 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA)
news.google.com • -
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8%
news.google.com • -
(SAVA) Technical Pivots with Risk Controls
news.google.com • -
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
globenewswire.com • -
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
marketbeat.com • -
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
seekingalpha.com • -
2 Biotech Stocks Making Moves Today
schaeffersresearch.com • -
Cassava Sciences News: Why Is SAVA Stock Trending Today?
investorplace.com • -
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
globenewswire.com • -
Get Your Money Out of These 3 Healthcare Stocks ASAP
investorplace.com • -
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
investorplace.com • -
Cassava Sciences Announces Expansion of Open-Label Extension Trials
globenewswire.com • -
Get Your Money Out of These 3 Biotech Stocks Before the End of July
investorplace.com • -
SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update
investorplace.com • -
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
investorplace.com • -
3 Healthcare Stocks to Sell in July Before They Crash & Burn
investorplace.com • -
Top 5 Health Care Stocks That May Explode In July
benzinga.com • -
3 Biotech Stocks to Sell in July Before They Crash & Burn
investorplace.com • -
Why Cassava Sciences Stock Is Sinking Today
fool.com •